Network | Cluster | Enrichment term | Nr. of associated genes | % of associated genes | Adj p-value |
---|---|---|---|---|---|
Lympho-myeloid | LM1 | Chemokine signaling pathwaya | 29/31 | 93.5 | 6.49e−55 |
LM2 | Antigen processing and presentationa | 6/6 | 100.0 | 5.78e−14 | |
LM3 | Focal adhesion | 31/33 | 93.9 | 2.54e−58 | |
LM4 | TNF signaling pathwaya | 20/41 | 48.8 | 3.72e−32 | |
LM5 | RIG-I-like receptor signaling pathwaya | 7/8 | 87.5 | 1.19e−15 | |
LM6 | Apoptosisa | 33/65 | 50.8 | 2.74e−52 | |
LM7 | MAPK signaling pathwaya | 44/71 | 62.0 | 1.4e−59 | |
LM8 | Wnt signaling pathway | 13/16 | 81.2 | 7.56e−24 | |
LM9 | positive regulation of interleukin-8 productiona | 6/12 | 50.0 | 5.92e−09 | |
LM10 | Interleukin-2 family signalinga | 3/3 | 100.0 | 2.46e−07 | |
LM11 | disulfide oxidoreductase activitya | 4/4 | 100.0 | 1.27e−09 | |
Diffuse-myeloid | DM1 | Focal adhesion | 34/45 | 75.6 | 7.1e−57 |
DM2 | PPAR signaling pathwaya | 22/28 | 78.6 | 1.11e−47 | |
DM3 | Dopaminergic synapsea | 23/30 | 76.7 | 8.94e−43 | |
DM4 | EPHA-mediated growth cone collapsea | 3/3 | 100.0 | 3.78e−08 | |
DM5 | Cam-PDE 1 activationa | 4/4 | 100.0 | 1.41e−13 | |
DM6 | Adherens junctiona | 5/6 | 83.3 | 1.35e−08 | |
Pauci-immune Fibroid | PF1 | Focal adhesion | 42/45 | 93.3 | 2.06e−79 |
PF2 | Ras signaling pathwaya | 49/64 | 76.6 | 1.09e−79 | |
PF3 | Wnt signaling pathway | 23/24 | 95.8 | 1.2e−12 | |
PF4 | Cytokine-cytokine receptor interactiona | 18/18 | 100.0 | 4.41e−37 | |
PF5 | VEGFR2 mediated vascular permeabilitya | 4/7 | 57.1 | 1.07e−06 | |
PF6 | Regulation of RUNX1 Expression and Activitya | 3/3 | 100.0 | 1.59e−07 | |
PF7 | TGF-beta signaling pathwaya | 9/14 | 64.3 | 6.25e−17 | |
PF8 | mTOR signalinga | 6/6 | 100.0 | 7.35e−16 | |
PF9 | Adrenergic signaling in cardiomyocytesa | 9/11 | 81.8 | 5.71e−16 | |
PF10 | Vascular smooth muscle contractiona | 12/19 | 63.2 | 2.75e−20 | |
Good Responders | R1 | PI3K-Akt signaling pathwayb | 34/64 | 53.1 | 3.76e−39 |
R2 | ECM-receptor interactionb | 7/7 | 100.0 | 2.74e−16 | |
R3 | Chemokine receptors bind chemokinesb | 6/6 | 100.0 | 1.07e−15 | |
R4 | MAP2K and MAPK activationb | 5/7 | 71.4 | 1.91e−10 | |
R5 | disulfide oxidoreductase activityb | 4/4 | 100.0 | 1.27e−09 | |
R6 | Triglyceride catabolismb | 3/3 | 100.0 | 3.77e−08 | |
R7 | Cam-PDE 1 activationb | 4/4 | 100.0 | 1.41e−13 | |
Non Responders | NR1 | Antigen processing and presentationb | 6/6 | 100.0 | 5.78e−14 |
NR2 | Chemokine signaling pathwayb | 25/25 | 100.0 | 1.6e−49 | |
NR3 | Wnt signaling pathwayb | 23/31 | 74.2 | 1.02e−16 | |
NR4 | VEGFR2 mediated vascular permeabilityb | 7/18 | 38.8 | 3.12e−14 | |
NR5 | Olfactory transductionb | 32/50 | 64.0 | 6.9e−10 | |
NR6 | RIG-I-like receptor signaling pathwayb | 5/6 | 83.3 | 4.88e−31 | |
NR7 | Platelet activation, signaling and aggregationb | 24/39 | 61.5 | 1.34e−17 |